Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
"Initial interim data from the Phase 1/2 study with STEM's HuCNS-SC cells in geographic atrophy age-related macular degeneration were extraordinarily encouraging." (7/31/14) StemCells Inc. - The Life Sciences Report Interview with Christopher James More >
Kimberly Lee, D.O., is a senior research analyst at ThinkEquity LLC, where she focuses on the biotechnology sector. Prior to joining ThinkEquity she covered the biotechnology industry for more than 11 years, most recently as a managing director at Global Hunter Securities LLC. She has also held sell-side roles at Stephens Inc., Jefferies & Co. Inc. and Wedbush Securities (formerly Pacific Growth Equities). Prior to her Wall Street career, Lee was trained as an obstetrician/gynecologist. She holds a bachelor's degree in biological sciences from Stanford University and earned her doctorate in osteopathic medicine from Kirksville College of Osteopathic Medicine.
ThinkEquity Analyst Bets on Extraordinary Science and Clinical Data (9/20/12) Investing in companies devoted to orphan diseases sounds counterintuitive, but Senior Research Analyst Kimberly Lee of ThinkEquity has singled out the space as one with the potential for huge returns. In this exclusive interview with The Life Sciences Report, Lee shares her very best ideas, identifying companies that will be propelled by vigorously growing revenues and will also appeal to investors who understand the unmet needs of patients and the numerous incentives available for developing life-saving drugs.
"I expect results from NBS' Phase 2 PreSERVE-AMI trial in Q4/14; that will be proof of concept for this approach." (9/10/14) NeoStem Inc. - The Life Sciences Report Interview with Vernon Bernardino More >